Myriad's Flurizan fails in Phase III Alzheimer's trial
This article was originally published in Scrip
Myriad Genetics' investigational Alzheimer's disease drug Flurizan (tarenflurbil) has failed in a closely watched Phase III trial.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.